Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05453773
Other study ID # OSU-22158
Secondary ID NCI-2022-05156R0
Status Completed
Phase N/A
First received
Last updated
Start date June 19, 2022
Est. completion date May 11, 2023

Study information

Verified date November 2023
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial evaluates how the content of waterpipe (WP) tobacco affects the appeal, puffing behavior, and toxicity of WP tobacco smoking. The data from the proposed study will provide direct links between WP tobacco's primary additives (sugars and humectants), CO and nicotine biomarkers, smoker preferences, perceptions of harm and puffing behaviors, and the subsequent range of toxicant exposures associated with these additives and behaviors. Study outcomes include waterpipe puffing behaviors, exhaled carbon monoxide levels, nicotine uptake, spirometry, sensory perceptions, smoking appeal, and risk perception. Waterpipe tobacco smoking is often the first combustible tobacco product tried by adolescents and young adults, possibly due to the widespread availability of heavily sweetened waterpipe tobacco and the perception that waterpipe smoking is a safer alternative to cigarette smoking. However, waterpipe tobacco smoking is associated with lung disease, carbon monoxide poisoning, and precursor conditions for oral and other cancers in adolescents and young adults. There is currently little data available on how the primary additives (by weight) in waterpipe tobacco affect puffing behaviors, toxicant exposures, pulmonary function and appeal. This clinical trial uses established waterpipe tobacco smokers, four investigational tobacco products with precisely manipulated levels of humectants and natural sugars in a single-blind, crossover (repeated measures) study design to determine how waterpipe tobacco additives effect human puffing behavior, nicotine uptake, flavor perceptions, lung function, and biomarkers of exposure.


Description:

Currently there are no regulations governing the content of WP tobacco. Because mandated changes in tobacco content may lead to unintended consequences that ultimately result in public health declines, human use behaviors must be well understood prior to implementing regulatory product standards. The proposed study will include preparing and characterizing the content of 4 investigational tobacco products (ITPs) (Aim 1); characterizing the mainstream smoke toxicant emissions from machine smoking the 4 ITPs using a single, established puffing regimen (Aim 2); measuring human puffing behavior, general harm and specific health risk and flavor perceptions, lung function, and biomarkers of exposure in a group of established WP smokers smoking the 4 ITPs in the laboratory (Aim 3), and estimating toxicant exposure ranges using machine smoking and puffing regimens derived from the human laboratory testing (Aim 4). The clinical trial (Aim 3) will focus on using a group of established adult and young adult WP smokers, a cross-over study design, CO and nicotine biomarkers, spirometry, cutting edge psychophysical measurement tools, and risk perception instruments to map the relationship between sensory experiences and preferences of sweetness and flavor to specific additive content in WP tobacco that affect these experiences, preferences, acute health effects, and toxicant exposures. Study subjects will participate in a series of 4 clinic sessions, each visit separated by at least a week, in which they smoke one of 4 tobacco preparations (single-blind) using a research grade waterpipe in a randomly assigned sequence in a smoking room with sufficiently controlled ventilation rate to keep ambient air CO levels below 25 ppm. Exhaled CO, whole blood samples and spirometry measures will be collected before and immediately after the smoking session. Taste perceptions, liking/disliking, and risk perceptions will be determined via questionnaires before, during, and after smoking.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date May 11, 2023
Est. primary completion date May 11, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: - Sufficient understanding of consent form and study procedures - Age 21-50 years old - Experienced WP smokers defined as having smoked a WP at least 3 times per month in the last month - Willing/able to abstain from nicotine product use for at least 12 hours prior to the laboratory visits - Willing to attend four laboratory sessions at the same time of day lasting approximately 3 hours (h) each - Read and speak English Exclusion Criteria: - Evident intoxication on any visit - Exhaled breath CO > 10 ppm - Pregnancy (known or suspected), trying to become pregnant, breastfeeding, unwillingness to use contraception for the duration of the study - Significant smoking-related disease (by history) - Any of the following in the past 30 days (self-report): - Uncontrolled asthma or asthma that is worse than usual - Severe respiratory allergies, such as wheezing, coughing, shortness of breath when exposed to known allergens - Acute upper or lower respiratory illnesses like the flu, common cold, or pneumonia - Any other serious lung infection or disease, such as tuberculosis, cystic fibrosis, or lung cancer - Hospitalization for difficulty breathing - Currently engaging in a WP tobacco smoking quit attempt

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire Administration
Ancillary studies
Behavioral:
Tobacco Smoking
Smoke waterpipe tobacco

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (4)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center Food and Drug Administration (FDA), National Cancer Institute (NCI), Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Exhaled breath carbon monoxide (CO) Assessing change from baseline (boost): collect before and immediately after each smoking session with a handheld electrochemical cell. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Plasma nicotine boost Assessing change from baseline (boost): Whole blood collected before and immediately after each smoking session, separated, and plasma layer transferred and stored at -80 °C until analysis for nicotine according to validated methods using LC-MS/MS. Up to 2 years
Primary Change in Forced vital capacity (FVC) Spirometer measurements will be collected. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Forced expiratory volume in 1 second (FEV1) Spirometer measurements will be collected. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in FEV1/FVC; The ratio of the forced expiratory volume in the first one second to the forced vital capacity of the lungs. Spirometer measurements will be collected. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Peak expiratory flow (PEF) Spirometer measurements will be collected. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Forced expiratory flow at 25-75% of FVC Spirometer measurements will be collected. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Tobacco use history Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Nicotine dependence Assessed by Hooked on Nicotine Checklist (HONC). 10 "Yes" or "No" questions, yes = 1, no = 0; minimum score = 0, maximum score = 10, higher scores mean greater nicotine dependence. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Nicotine dependence Lebanese Waterpipe Dependence Scale (LWDS). Ten questions, min score = 0, max score = 36, higher sores mean greater nicotine dependence. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary General harm and specific health risk perceptions Assessed using harm/health risk perceptions questionnaire. Min scale = 0 (no harm), max scale = 10 (extreme harm). Higher scores mean greater perceived harm/health risk. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Subjective effects of smoking tobacco Assessed using Direct Effects of Tobacco scale. Min scale = 0 (not at all), Max scale = extremely. Higher number total means tobacco has greater effect. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Subjective effects of smoking tobacco Assessed change from baseline using Direct Effects of Nicotine scale. Min scale = 0 (not at all), Max scale = 100 (extremely). Higher number means nicotine has greater effect. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Subjective effects of smoking tobacco Assessed change from baseline using Questionnaire for Urges to Smoke. Min scale: 1 (strongly disagree), Max scale = 6 (strongly agree). Higher number means greater urge to smoke. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Change in Nicotine withdrawal assessment Assessed change from baseline using Waterpipe-modified Minnesota Withdrawal Scale. Min scale = 0 (not at all), Max scale = 100 (extremely). Higher number total means greater withdrawal symptoms. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Tobacco flavors perception, intensity of sweetness To determine the relative intensity of specific flavors, e.g., sweetness, will use the general version of the Labeled Magnitude Scale (gLMS), to obtain data that would permit ratio comparisons of perceived sensation magnitudes. Min scale = 0, Max scale = 100. Higher number means perception is stronger. Up to 2 years
Primary Tobacco flavors perception, degree of liking or disliking To assess the degree of liking or disliking of flavors, will use the Labeled Hedonic Scale (LHS) to collect ratio-level data on the magnitude of liking and disliking of sensation. Min scale = 0, Max scale = 100. Higher number means greater liking. Up to 2 years
Primary Puffing topography Puff volume will be measured continuously during the smoking session using the research-grade waterpipe. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Puffing topography Puff duration will be measured continuously during the smoking session using the research-grade waterpipe. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Puffing topography Puff average flow rate will be measured continuously during the smoking session using the research-grade waterpipe. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Puffing topography Puff peak flow rate will be measured continuously during the smoking session using the research-grade waterpipe. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
Primary Puffing topography Interpuff interval will be measured continuously during the smoking session using the research-grade waterpipe. Data will be analyzed using linear mixed models containing random subject effects. Since linear mixed models allow for incomplete data, data from all completed smoking sessions will be used in the analysis. Tukey's method will be used to adjust for multiple comparisons of the tobacco treatments. Up to 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06315881 - Informing Oral Nicotine Pouch Regulations to Promote Public Health Phase 2
Active, not recruiting NCT02964182 - Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Completed NCT04510077 - SmartQuit Program for Smoking Cessation N/A
Completed NCT03200236 - The Lung Screening, Tobacco and Health Project Phase 3
Recruiting NCT06448351 - Manipulating E-Cigarette Nicotine to Promote Public Health N/A
Recruiting NCT05730439 - Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio Appalachia Early Phase 1
Recruiting NCT04949464 - Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study N/A
Not yet recruiting NCT06249984 - Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff N/A
Enrolling by invitation NCT04969978 - Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation N/A
Completed NCT05972941 - Nicotine and Tobacco Message Framing Among LGBT Young Adults N/A
Withdrawn NCT05411107 - Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Phase 2
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Recruiting NCT04340531 - Effectiveness of a Multi-Level Smoking Cessation Program for High-Risk Women in Rural Communities Phase 4
Terminated NCT04297332 - Episodic Future Thinking and Future Thinking Priming for Smoking Cessation N/A
Completed NCT03402230 - Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers Early Phase 1
Recruiting NCT05876091 - Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography N/A
Completed NCT03182959 - Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer Early Phase 1
Completed NCT05393869 - Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults N/A
Recruiting NCT05679349 - Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking N/A

External Links